Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer

Human Gene Therapy

Volumn 10, Issue 6, 1999, Pages 995-1008

  Rochaix, P ^a   Delesque, N ^a   Esteve J P ^a   Saint Laurent, N ^a   Voigt, J J ^a   Vaysse, N ^a   Susini, C ^a   Buscail, L ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PANCREAS ADENOCARCINOMA; RECEPTOR GENE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; UP-REGULATION;

EID: 0033541523     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018391     Document Type: Article

References (55)

1. ARNOLD, R., BENNING, R., NEUHAUS, R., ROLWAGE, M., and TRAUTMANN, M.E. (1993). Gastroenteropancreatic endocrine tumours: Effect of sandostatin on tumour growth. Digestion 54, 72-75.
2. BARBA, D., HARDIN, J., RAY, J., and GAGE, F.H. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
3. BELL, G.I., and REISINE, T. (1993). Molecular biology of somatostatin receptors. Trends Neurosci. 16, 34-38.
4. BRADFORD, M.M. (1976). A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of dye binding. Anal. Biochem. 72, 248-254.
5. BRUNO, J.F., XU, Y., and BERELOWITZ, M. (1994). Somatostatin receptor subtype mRNA expression in GH3 cells. Biochem. Biophys. Res. Commun. 202, 1738-1743.
6. BUSCAIL, L., DELESQUE, N., ESTÈVE, J.-P., SAINT-LAURENT, N., PRATS, H., CLERC, P., ROBBERECHT, P., BELL, G.I., LIEBOW, C., SCHALLY, A.V., VAYSSE, N., and SUSINI, C. (1994). Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. U.S.A. 91, 2315-2319.
7. BUSCAIL, L., ESTÈVE, J.-P., SAINT-LAURENT, N., BERTRAND, V., REISINE, T., O'CARROLL, A.-M., BELL, G.I., SCHALLY, A.V., VAYSSE, N., and SUSINI, C. (1995). Inhibition of cell proliferation by the somatostatin analogues RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 92, 1580-1584.
8. BUSCAIL, L., SAINT-LAURENT, N., CHASTRE, E., VAILLANT, J.C., GESPACH, C., CAPELLÀ, G., KALTHOFF, H., LLUIS, F., VAYSSE, N., and SUSINI, C. (1996). Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56, 1823-1827.
9. CHAYVIALLE, J.A., MIYATA, M., RAYFORD, P.L., and THOMPSON, J.C. (1980). Effect of test meal, intragastric nutrients and intraduodenal bile on plasma concentrations of immunoreactive somatostatin and vasoactive intestinal peptide. Gastroenterology 79, 844-852.
10. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single step method of RNa isolation by acid guanidium thiocyanata-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
11. CLARY, B.M., COVENEY, E.C., PHILIP, R., BLAZER, D.G., III, MORSE, M., GILBOA, E., and LYERLY, H.K. (1997). Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther. 4, 97-104.
12. COLOMBO, B.M., BENEDETTI, S., OTTOLENGHI, S., MORA, M., POLLO, B., POLI, G., and FINOCCHIARO, G. (1995). The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6, 763-772.
13. DELESQUE, N., BUSCAIL, L., ESTÈVE, J.P., SAINT-LAURENT, N., MÜLLER, C., WECKBECKER, G., BRUNS, C., VAYSSE, N., and SUSINI, C. (1997). sst2 somatostatin receptor expression reverses the tumorigenicity of human pancreatic cancer cells. Cancer Res. 56, 1823-1827.
14. DENNING, C., and PITTS, J.D. (1997). Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther. 8, 1825-1835.
15. DIMAIO, J.-M., CLARY, B.M., VIA, D.F., COVENEY, E., PAPPAS, T.N., and LYERLY, H.K. (1994). Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116, 205-213.
16. DUKAS, K., SARFATI, P., VAYSSE, N., and PRADAYROL, L. (1993). Quantification of changes in the expression of multiple genes by simultaneous polymerase chain reactions. Anal. Biochem. 215, 66-72.
17. ELSHAMI, A.A., SAAVEDRA, A., ZHANG, H., KUCHARCZUK, J.C., SPRAY, D.C., FISHMAN, G.I., AMIN, K.M., KAISER, L.R., and ALBELDA, S.M. (1996). Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85-92.
18. FLORIO, T., RIM, C., HERSHBERGER, R.E., LODA, M., and STORK, J.S. (1994). The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphate activity in CHO-K1 cells. Mol. Endocrinol. 8, 1289-1297.
19. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
20. FRIESS, H., BUCHLER, M., BEGLINGER, C., WEBER, A., KUNZ, J., FRITSCH, K., DENNLER, H.J., and BEGER, H.G. (1993). Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8, 540-545.
21. GAGANDEEP, S., BREW, R., GREEN, B., CHRISTMAS, S.E., KLATZMANN, D., POSTON, G.J., and KINSELLA, A.R. (1996). Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 3, 83-88.
22. HARRIS, J.D., GUTIERREZ, A.A., HURST, H.C., SIKORA, K., and LEMOINE, N.R. (1994). Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1, 170-175.
23. HO, L.T., CHEN, R.L., CHOU, T.Y., FONG, J.C., WANG, P.S., and CHOU, C.K. (1986). Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects - a two-compartment open model. Clin. Physiol. Biochem. 4, 257-267.
24. HOYER, D., BELL, G.I., BERELOWITZ, M., EPELBAUM, J., FENIUK, W., HUMPHREY, P.P.A., O'CARROLL, A.-M., PATEL, Y.C., SCHONBRUNN, A., TAYLOR, J.E. and REISINE, T. (1995). Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16, 86-88.
25. HUGUIER, M., SAMANA, G., TESTART, J., MAUBAN, S., FINGERHUT, A., NASSAR, J., HOURY, S., JAECK, D., DE MESTIER, P., FAVRE, J.P., MICHOT, F., VIDREQUIN, A., MANTION, G., VEYRIÈRES, M., FOURTANIER, G., LOINTIER, P., and GIGNOUX, M. (1992). Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am. J. Surg. 164, 348-353.
26. HUKOVIC, N., PANETTA, R., KUMAR, U., and PATEL, Y.C. (1996). Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology 137, 4046-4049.
27. KIANMANESH, A.R., PERRIN, H., PANOIS, Y., FABRE, M., NAGY, H.J., HOUSSIN, D., and KLATZMANN, D. (1997). A "distant" bystander effect of suicide gene therapy: Regression of non-transduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8, 1807-1814.
28. KNUTHSEN, S., ESTÈVE, J.-P., BERNADET, B., VAYSSE, N., and SUSINI, C. (1988). Molecular characterization of the solubilized receptor of somatostatin from rat pancreatic acinar membranes. Biochem. J. 254, 641-647.
29. KUHN, J.M., LEGRAND, A., RUIZ, J.M., OBACH, R., DE RONZAN, J., and THOMAS, F. (1994). Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol. 38, 213-219.
30. LAMBERTS, S.W.J., KRENNING, E.P., and REUBI, J.C. (1991). The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev 12, 450-482.
31. LEWIN, M.J.M. (1992). The somatostatin receptors in the GI tract. Annu. Rev. Physiol. 54, 455-469.
32. LIAPAKIS, G., HOEGER, C., RIVIER, J., and REISINE, T. (1996). Development of a selective agonist at the somatostatin receptor subtype SSTR1. J. Pharm. Exp. Ther. 276, 1089-1094.
33. LOPEZ, F., ESTÈVE, J.-P., BUSCAIL, L., DELESQUE, N., SAINT-LAURENT, N., THÉVENIAU, M., NAHMIAS, C., VAYSSE, N., and SUSINI, C. (1997). The tyrosine phosphatase SHP-1 associates with sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J. Biol. Chem. 272, 24448-24454.
34. NICHOLLS, J., WYNICK, D., DOMIN, J., SANDLER, L.M., and BLOOM, S.R. (1990). Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin. Endocrinol. (Oxford) 3, 545-350.
35. PAGÉS, P., BUSCAIL, L., DELESQUE, N., SAINT-LAURENT, N., ESTÈVE. J.-P., TKACZUK, J., VAYSSE, N., and SUSINI, C. (1997). G1 cell-cycle arrest and up-regulation of p27kipl expression after activation of somatostatin sst2 receptor. Gastroenterology 112, 635A.
36. PATEL, Y.C., SRIKANT, C.B., HUKOVIC, N., KUMAR, U., SHARMA, K., PANETTA, R., ROCHEVILLE, M., SASI, R., PUEBLA, L., and KHARE, S. (1997). Somatostatin receptors: Subtype selectivity for desensitization and antiproliferation. J. Endocrinol. Invest. 20 (Suppl. 7), 14-16.
37. PEPLINSKI, G.R., TSUNG, K., MEKO, J.B., and NORTON, J.A. (1995). In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery 118, 185-190.
38. POLLACK, M.N., and SCHALLY, A.V. (1998). Mechanism of antineoplastic action of somatostatin analogues. Proc. Soc. Exp. Biol. Med. 217, 143-152.
39. RADULOVIC, S., COMARU-SCHALLY, A.M., MILOVANOVIC, S., and SCHALLY, A.V. (1993). Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas 8, 88-97.
40. RAMESH, R., MUNSHI, A., ABBOUD, C.N., MARROGI, A.J., and FREEMAN, S.M. (1996). Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Hum. Gene Ther. 3, 376-384.
41. RAULY, I., SAINT-LAURENT, N., DELESQUE, N., BUSCAIL, L., ESTÈVE, J.-P., VAYSSE, N., and SUSINI, C. (1996). Induction of autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. J. Clin. Invest. 97, 1874-1883.
42. RAYNOR, K., MURPHY, W.A., COY, D.H., TAYLOR, J.E., MOREAU, J.P., YASUDA, K., BELL, G.I., and REISINE, T. (1993a). Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity of linear peptides. Mol. Pharmacol. 43, 838-844.
43. RAYNOR, K., O'CARROLL, A.-M., KONG, H., YASUDA, K., MAHAN, L.C., BELL, G.I., and REISINE, T. (1993b). Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol. Pharmacol. 44, 385-392.
44. REUBI, J.-C., HORISBERGER, C.E., ESSED, C.E., JEEKEL, J., KLIJN, J.G.H., and LAMBERTS, S.W.J. (1988). Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95, 760-763.
45. ROSENFELD, M.E., VICKERS, S.M., RABEN, D., WANG, M., SAMPSON, L., FENG, M., JAFFEE, E., and CURIEL, T. (1997). Pancreatic carcinoma cell killing via adenoviral mediated delivery of herpes simplex virus thymidine kinase gene. Ann. Surg. 225, 609-620.
46. SOINI, Y., PAAKKO, P., and LEHTO, V.P. (1998). Histopathological evaluation of apoptosis in cancer. Am. J. Pathol. 153, 1041-1053.
47. STURTZ, F.G., WADDELL, K., SHULOK, J., CHEN, X., CARUSO, M., SANSON, M., SNODGRASS, H.R., and PLATIKA, D. (1997). Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: Implications for gene therapy. Hum. Gene Ther. 8, 1945-1953.
48. UPP, J.R., JR., OLSON, D., POSTON, G.J., ALEXANDER, R.W., TOWNSEND, C.M., JR., and THOMPSON, J.C. (1988). Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am. J. Surg. 155, 29-35.
49. VAN EIJCK, C.H., LAMBERTS, S.W., LEMAIRE, L.C., JEEKEL, H., BOSMAN, F.T., REUBI, J.-C., BRUINING, H.A., and KRENNING, E.P. (1996). The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann. Surg. 224, 119-124.
50. VAYSSE, N., CHAYVIALLE, J.A., PRADAYROL, L., ESTEVE, J.-P. SUSINI, C., LAPUELLE, J., DESCOS, F., and RIBET, A. (1981). Somatostatin 28: Comparison with somatostatin 14 for plasma kinetics and low-dose effects on the exocrine pancreas in dogs. Gastroenterology 81, 700-706.
51. VIDAL, C., RAULY, I., ZEGGARI, M., DELESQUE, N., ESTÈVE, J.-P., SAINT-LAURENT, N., VAYSSE, N., and SUSINI, C. (1994). -Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol. Pharmacol. 45, 97-104.
52. WARSHAW, A.L., and FERNANDEZ-DEL-CASTILLO, C. (1992). Pancreatic carcinoma. N. Engl. J. Med. 326, 455-165.
53. WECKBECKER, G., RAULF, F., STOLZ, F., and BRUNS, C. (1993). Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 60, 245-260.
54. YANG, L., HWANG, R., PANDIT, L.P., DANENBERG, K.D., GORDON, E.M., ANDERSON, W.F., and PAREKH, D. (1996). Gene therapy of metastasis pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 224, 405-417.
55. YANG, L., CHIANG, Y., LENZ, H.-J., DANENBERG, K.D., SPEARS, C.P., GORDON, E.M., ANDERSON, W.F., and PAREKH, D. (1998). Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. 9, 719-728.